Sage Therapeutics

372 articles about Sage Therapeutics

• Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

  11/2/2021

  Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the third quarter ended September 30, 2021.

• 

  Aduhelm Falls Drastically Short of Projections as Biogen Spins Positives

  10/20/2021

  Biogen’s Aduhelm (aducanumab) reported only $300,000 in third-quarter sales compared to original analyst average estimates of $10.79 million.

• Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022

  10/19/2021

  Sage Therapeutics, Inc. and Biogen Inc. announced their plan to submit a New Drug Application to the U.S. Food and Drug Administration for zuranolone, an investigational two-week, once-daily therapeutic in the second half of 2022.

• Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress

  10/4/2021

  Sage Therapeutics, Inc. and Biogen Inc. announced new data from the LANDSCAPE and NEST clinical development programs evaluating the efficacy and safety of zuranolone for the treatment of major depressive disorder and postpartum depression presented at the 34th European College of Neuropsychopharmacology Congress, taking place October 2-5, 2021.

• 

  Biogen and Sage Present Positive Data for Breakthrough Depression Therapy

  10/4/2021

  Sage Therapeutics and Biogen announced positive results from their ongoing clinical trials on the efficacy and safety of zuranolone in treating major depressive disorder and postpartum depression. 

• Sage Therapeutics Launches SageCitizen Social Impact Initiative

  10/1/2021

  Sage Therapeutics, a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced the launch of SageCitizen – a corporate social impact effort that activates and amplifies Sage’s long-term commitment to People, Patients, Planet and Community.

• 

  BioSpace Movers & Shakers, Sept. 24

  9/24/2021

  Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

• Sage Therapeutics Appoints Chris Benecchi as Chief Commercial Officer

  9/21/2021

  Sage Therapeutics, a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced the appointment of Chris Benecchi as Chief Commercial Officer.

• Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington’s Disease

  9/15/2021

  Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that the U.S. Food and Drug Administration has granted Fast Track Designation to SAGE-718 for development as a potential treatment for Huntington’s disease.

• 

  FDA Grants Key Approvals to Potential Rare and Serious Disease Treatments

  9/15/2021

  FDA has been actively greenlighting a number of efforts over the last few days to push therapies for rare or serious diseases that have largely unmet medical needs. Here's a look.

• Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference - Sep 02, 2021

  9/2/2021

  Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that the Company will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 10 at 12:30pm ET.

• 

  Clinical Catch-Up: August 2-6

  8/9/2021

  It was a busy week for clinical trial announcements. Take a look.

• Sage Therapeutics to Present at Upcoming August Investor Conferences

  8/4/2021

  Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present at the following upcoming investor conferences in August:

• Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

  8/3/2021

  Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the second quarter ended June 30, 2021.

• 

  Positive Results in Hand, Sage Scraps Two Phase III Zuranolone Studies

  8/3/2021

  Sage announced the termination of the REDWOOD and RAINFOREST studies of zuranolone, which is being assessed to treat both major depressive disorder and post-partum depression. 

• Sage Therapeutics to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

  7/20/2021

  Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced it will host a live webcast on Tuesday, August 3, 2021 at 8:00 a.m. ET to announce second quarter 2021 financial results and discuss recent business updates.

• Sage Therapeutics to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

  7/8/2021

  Sage Therapeutics, Inc. today announced that the Company will participate in a fireside chat at Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on July 13 th at 2:25pm ET.

• Sage Therapeutics to Participate in SVB Leerink’s 3rd Annual CNS Forum

  6/24/2021

  Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that the Company will participate in a fireside chat at SVB Leerink’s 3rd Annual CNS Forum on June 29th at 4:15pm ET.

• Sage Therapeutics to Host Conference Call

  6/15/2021

  Sage Therapeutics today announced it will host a live webcast this morning, June 15, 2021 at 8:00 a.m. ET to review topline results from the Phase 3 WATERFALL Study evaluating zuranolone for major depressive disorder.

• Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

  6/15/2021

  Sage Therapeutics, Inc. and Biogen Inc. announced that the WATERFALL Study in patients with MDD met its primary endpoint with zuranolone 50 mg showing statistically significant improvement in depressive symptoms compared with placebo at Day 15 as assessed by the 17-item Hamilton Rating Scale for Depression total score.